Jun. 23 2022
Source Page: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyFound: emic myelosis or diguglielmo* or di guglielmo* ).tw,kf.13447 11 ((mast-cell* or mastcell*) adj2 leu
May. 31 2022
Source Page: Freedom of Information responses from the MHRA - week commencing 27 December 2021Found: cell activation syndrome70 Methaemoglobinaemia10 Haemolyses NEC Haemolysis60 Intravascular
Dec. 29 2021
Source Page: Freedom of Information responses from the MHRA - week commencing 14 July 2021Found: Eosinophilic disorders Eosinophilia10 Haematological disorders Blood disorder10 Mast
Dec. 09 2021
Source Page: Coronavirus Vaccines - summary of Yellow Card reportingFound: cell activation syndrome100 Mastocytosis30 Methaemoglobinaemia10 Haemolyses NEC
Dec. 09 2021
Source Page: Coronavirus Vaccines - summary of Yellow Card reportingFound: Antiphospholipid syndrome10 Coagulopathy10 Haematological disorders Blood disorder10 Mast
Dec. 09 2021
Source Page: Coronavirus Vaccines - summary of Yellow Card reportingFound: cell activation syndrome70 Methaemoglobinaemia10 Haemolyses NEC Haemolysis60 Intravascular
Feb. 02 2022
Source Page: Palforzia for treating peanut allergy in children and young peopleFound: TEAE Treatment-emergent adverse event TESAE Treatment-emergent serious adverse event TH2 Helper T-cell
Sep. 22 2021
Source Page: Midostaurin for treating advanced systemic mastocytosisFound: Upon exposure to potential triggers of mast cell activation, patients can also experience systemic
Feb. 02 2022
Source Page: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsFound: Once the immune system is activ ated, dendritic cells, mast cell s and macrophages produce proinflammatory
Sep. 01 2021
Source Page: Shingles vaccination: guidance for healthcare professionalsFound: CT Flu/COVID/Shingles IMMDX_COD diseases of immune deficiency 93205000 Malignant mast cell tumour of